The Science of Transformation 

Advanced genetic medicine meets clinical accessibility

Our proprietary MultiPlex™ CAR-T for cancer represents a breakthrough in genetic medicine – a transformative system capable of delivering complex, multi-gene therapeutic constructs directly in patients with weeks-long precision expression.

Core Innovation: 

  • MultiPlex Delivery: Up to 20kb genetic payloads enabling multi-gene therapeutic strategies
  • Optimal Durability: Weeks-long expression providing ideal therapeutic window
  • Precise Targeting: Enhanced cellular uptake with minimal off-target effects
  • Safety-by-Design: Non-viral approach eliminates genomic integration risks
  • Large Payloads: Exceptionally large RNA payloads with self-amplification to deliver multiple proteins for complex therapeutic challenges

The MultiPlex™ Advantage

Current in vivo approaches face fundamental limitations:
  • Viral vectors: Safety risks, payload restrictions, immunogenicity
  • Traditional LNPs: Short duration, limited capacity

The MultiPlex™ Solution

Self-amplifying RNA technology combined with advanced targeting delivers unprecedented capability for complex therapeutic programming directly in vivo.

Advanced therapeutic strategies across multiple indications

Designed for Broad Therapeutic Impact

 
We are advancing MultiPlex in vivo Car-T for oncology and autoimmune disease while driving innovative immuno-oncology combinations with high potency and large payload capacity.
 
Additional Opportunities
  • Vaccines: Cancer, Infectious Disease
  • Genetic Disorders: Gene Addition/Silencing

Scalable delivery infrastructure for worldwide patient accessibility

Built for Global Impact 

 
  • Off-the-shelf production eliminates patient-specific manufacturing 
  • Scalable delivery infrastructure for worldwide patient accessibility
Close